Hepatitis C New Drugs Review
21.4K views | +0 today
Follow
 
Rescooped by Krishan Maggon from Top Selling Monoclonal Antibodies 2014
onto Hepatitis C New Drugs Review
Scoop.it!

Current and Future Therapies for Hepatitis C Virus Infection — NEJM

In their review of drug therapy for chronic hepatitis C infection, Liang and Ghany (May 16 issue)1 summarize boceprevir- and telaprevir-based regimens. Figure 2 of the article describes the regimens according to the response ...
more...
No comment yet.
Hepatitis C New Drugs Review
FDA approved Incivek(telaprevir, Vertex) on Monday 23 May by its PDUFA deadline.A paradigm shift in the treatment of Hepatitis C virus infection. http://knol.google.com/k/krishan-maggon/boceprevir-merck-telaprevir-vertex/3fy5eowy8suq3/151#
Curated by Krishan Maggon
Your new post is loading...
Your new post is loading...
Scooped by Krishan Maggon
Scoop.it!

Created public version #121 of the knol: "Boceprevir (Merck) & Telaprevir (Vertex) Hepatitis C : FDA Review & Approval"

Created public version #121 of the knol: "Boceprevir (Merck) & Telaprevir (Vertex) Hepatitis C : FDA Review & Approval" | Hepatitis C New Drugs Review | Scoop.it
Krishan Maggon published version 121 of a knol titled: "Boceprevir (Merck) & Telaprevir (Vertex) Hepatitis C : FDA Review & Approval"...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Busting the Billion-Dollar Myth: How to Slash the Cost of Drug Development

Busting the Billion-Dollar Myth: How to Slash the Cost of Drug Development | Hepatitis C New Drugs Review | Scoop.it
A nonprofit organization that creates new drugs for neglected diseases proves development doesn't have to cost a fortune. Can its model work more broadly?
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

The response to the inactivated Hepatitis A vaccine in children with autoinflammatory diseases: a prospective observational controlled study

The response to the inactivated Hepatitis A vaccine in children with autoinflammatory diseases: a prospective observational controlled study | Hepatitis C New Drugs Review | Scoop.it
In this study we aimed to describe the immunogenicity and side effects of the HAV vaccine on patients with AID on immunomodulating treatment, not previously exposed to HAV, and compare this against healthy controls. This was a prospective observational matched controlled study including patients with FMF, hyper-IgD syndrome (HIDS), familial cold auto-inflammatory syndrome and systemic JIA (SJIA). T
Krishan Maggon 's insight:
Rheumatology (2016) 55 (9): 1705-1706. doi: 10.1093/rheumatology/kew239 First published online: June 15, 2016
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease | Oussalah | Oncotarget

BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease | Oussalah | Oncotarget | Hepatitis C New Drugs Review | Scoop.it

BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease


ABSTRACT The molecular mechanisms of hepatocellular carcinoma (HCC) carcinogenesis are still not fully understood. DNA repair defects may influence HCC risk. The aim of the study was to look for potential genetic variants of DNA repair genes associated with HCC risk among patients with alcohol- or viral-induced liver disease. We performed four case-control studies on 2,006 European- (Derivation#1 and #2 studies) and African-ancestry (Validation#1 and #2 studies) patients originating from several cohorts in order to assess the association between genetic variants on DNA repair genes and HCC risk using a custom array encompassing 94 genes. In the Derivation#1 study, the BRIP1 locus reached array-wide significance (Chi-squared SV-Perm, P=5.00×10–4) among the 253 haplotype blocks tested for their association with HCC risk, in patients with viral cirrhosis but not among those with alcoholic cirrhosis. The BRIP1 haplotype block included three exonic variants (rs4986763, rs4986764, rs4986765). The BRIP1 ‘AAA’ haplotype was significantly associated with an increased HCC risk [odds ratio (OR), 2.01 (1.19–3.39); false discovery rate (FDR)-P=1.31×10–2]. In the Derivation#2 study, results were confirmed for the BRIP1 ‘GGG’ haplotype [OR, 0.53 (0.36–0.79); FDR-P=3.90×10–3]. In both Validation#1 and #2 studies, BRIP1 ‘AAA’ haplotype was significantly associated with an increased risk of HCC [OR, 1.71 (1.09–2.68); FDR-P=7.30×10–2; and OR, 6.45 (4.17–9.99); FDR-P=2.33×10–19, respectively]. Association between the BRIP1 locus and HCC risk suggests that impaired DNA mismatch repair might play a role in liver carcinogenesis, among patients with HCV- or HBV-related liver disease.


Keywords: DNA repair genes, hepatocellular carcinoma, BRIP1, hepatitis B virus, hepatitis C virus

Krishan Maggon 's insight:
Oncotarget. 2016 Aug 17. doi: 10.18632/oncotarget.11327. [Epub ahead of print] 

BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease. 

Oussalah A1,2, Avogbe PH1, Guyot E3, Chery C1,2, Guéant-Rodriguez RM1,2, Ganne-Carrié N4,5, Cobat A6,7, Moradpour D8, Nalpas B9, Negro F10, Poynard T11, Pol S9,12, Bochud PY13, Abel L6,7,14, Jeulin H15, Schvoerer E15, Chabi N16, Amouzou E17, Sanni A16, Barraud H18, Rouyer P1, Josse T2, Goffinet L1, Jouve JL19, Minello A19, Bonithon-Kopp C19, Thiefin G20, Di Martino V21, Doffoël M22, Richou C21, Raab JJ23, Hillon P19, Bronowicki JP1,18, Guéant JL1,2, Study Group FT.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Immune-based Therapy Clinical Trials in Hepatocellular Carcinoma | Open Access | OMICS International

Immune-based Therapy Clinical Trials in Hepatocellular Carcinoma | Open Access | OMICS International | Hepatitis C New Drugs Review | Scoop.it
Immune-based Therapy Clinical Trials in Hepatocellular Carcinoma, Journal of Clinical & Cellular Immunology.

Abstract Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality and continues to increase. Current standard of care for patients with HCC only provides limited therapeutic benefit. Development of innovative strategies is urgently needed. Experience with immunotherapy in HCC is quite early, but rapidly rise in the recent 15 years. Multifaceted immune-based approaches have shown efficacy in achieving disease regression, representing the most promising new treatment approach. Here, we classify the ongoing or completed clinical trials in HCC in terms of the immune strategies to be used and assess their clinical outcomes. The generated information may be helpful in the design of future immune-based therapies for achieving ideal tumor control and maximizing anti-tumor immunity.
Krishan Maggon 's insight:
Citation: Liu D, Staveley-O’Carroll KF, Li G (2015) Immune-based Therapy Clinical Trials in Hepatocellular Carcinoma. J Clin Cell Immunol 6:376. doi:10.4172/2155-9899.1000376
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

New developments in proprotein convertase subtilisin–kexin 9... : Current Opinion in Lipidology

New developments in proprotein convertase subtilisin–kexin 9... : Current Opinion in Lipidology | Hepatitis C New Drugs Review | Scoop.it

Abstract 

Purpose of review: High levels of LDL-cholesterol (LDL-C) are directly associated with devastating cardiovascular complications. Statins downregulate cholesterol synthesis and upregulate hepatic mRNA levels of LDL receptor (LDLR) and proprotein convertase subtilisin–kexin 9 (PCSK9), a validated enhancer of LDLR protein degradation. Herein, we summarize recent discoveries of the biological properties of PCSK9 in both health and disease states. 

 Recent findings: PCSK9 downregulation of the LDLR protein likely explains the observed protective effect of the loss of PCSK9 in reducing lipoprotein(a) and incidence of septic shock. Injectable inhibitory PCSK9 monoclonal antibodies are now prescribed to hypercholesterolemic patients that do not reach target levels of LDL-C with available drugs. PCSK9 also reduces the levels of other receptors, for example, VLDL receptor (VLDLR), ApoER2, CD36, and CD81. The efficacy of the upregulation of LDLR and VLDLR cell surface levels in the absence of PCSK9 is both tissue and sex dependent. As LDLR, CD81, and VLDLR are hepatitis C receptors, PCSK9 may protect against certain viral infections. 

 Summary: New functions of PCSK9 and other receptor targets are beginning to emerge to explain the observed changes in LDL-C and triglycerides. The effect of PCSK9 loss-of-function on glucose metabolism, factors that regulate the expression of PCSK9, and the roles of PCSK9 in other tissues, for example, intestine, kidney, and brain require further investigations.
Krishan Maggon 's insight:
Current Opinion in Lipidology: June 2016 - Volume 27 - Issue 3 - p 274–281 doi: 10.1097/MOL.0000000000000295 LIPID METABOLISM: Edited by G. Kees Hovingh and Jan Albert Kuivenhoven
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

High resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end stage liver disease

High resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end stage liver disease | Hepatitis C New Drugs Review | Scoop.it
HCV is an RNA virus that exists as a quasispecies of closely related genomes that are under continuous selection by host innate and adaptive immune responses and antiviral drug therapy. The primary site of HCV replication is the liver and yet our understanding of the spatial distribution of viral variants within the liver is limited. High resolution sequencing of HCV and monitoring of innate immune responses at multiple sites across the liver identified a uniform pattern of diversity and argues against viral compartmentalization. 

Keywords: Hepatitis C, ESLD, Evolution, Compartmentalization, Innate immunity
Krishan Maggon 's insight:
DOI: http://dx.doi.org/10.1016/j.jhep.2016.07.048

J Hepatol. 2016 Aug 13. pii: S0168-8278(16)30424-X. doi: 10.1016/j.jhep.2016.07.048. [Epub ahead of print] 

High resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end stage liver disease. 

Hedegaard DL1, Tully DC2, Rowe IA1, Reynolds GM3, Bean DJ2, Hu K1, Davis C1, Wilhelm A3, Ogilvie CB2, Power KA2, Tarr AW4, Kelly D5, Allen TM2, Balfe P6, McKeating JA7.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

2016 IAPAC International Conference on Viral Hepatitis Conference

2016 IAPAC International Conference on Viral Hepatitis Conference | Hepatitis C New Drugs Review | Scoop.it
RT @benyoungmd: ICYMI: @IAPAC/@UCSF's 2016 Int'l Conf on Viral #Hepatitis- presentations available. #HCV #HBV https://t.co/6yyOmJAbw7
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis — NEJM

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis — NEJM | Hepatitis C New Drugs Review | Scoop.it

Original Article from The New England Journal of Medicine — A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis


BACKGROUND Primary biliary cholangitis (formerly called primary biliary cirrhosis) can progress to cirrhosis and death despite ursodiol therapy. Alkaline phosphatase and bilirubin levels correlate with the risk of liver transplantation or death. Obeticholic acid, a farnesoid X receptor agonist, has shown potential benefit in patients with this disease. 

METHODS In this 12-month, double-blind, placebo-controlled, phase 3 trial, we randomly assigned 217 patients who had an inadequate response to ursodiol or who found the side effects of ursodiol unacceptable to receive obeticholic acid at a dose of 10 mg (the 10-mg group), obeticholic acid at a dose of 5 mg with adjustment to 10 mg if applicable (the 5–10-mg group), or placebo. The primary end point was an alkaline phosphatase level of less than 1.67 times the upper limit of the normal range, with a reduction of at least 15% from baseline, and a normal total bilirubin level. 

RESULTS Of 216 patients who underwent randomization and received at least one dose of obeticholic acid or placebo, 93% received ursodiol as background therapy. The primary end point occurred in more patients in the 5–10-mg group (46%) and the 10-mg group (47%) than in the placebo group (10%; P<0.001 for both comparisons). Patients in the 5–10-mg group and those in the 10-mg group had greater decreases than those in the placebo group in the alkaline phosphatase level (least-squares mean, −113 and −130 U per liter, respectively, vs. −14 U per liter; P<0.001 for both comparisons) and total bilirubin level (−0.02 and −0.05 mg per deciliter [−0.3 and −0.9 μmol per liter], respectively, vs. 0.12 mg per deciliter [2.0 μmol per liter]; P<0.001 for both comparisons). Changes in noninvasive measures of liver fibrosis did not differ significantly between either treatment group and the placebo group at 12 months. Pruritus was more common with obeticholic acid than with placebo (56% of patients in the 5–10-mg group and 68% of those in the 10-mg group vs. 38% in the placebo group). The rate of serious adverse events was 16% in the 5–10-mg group, 11% in the 10-mg group, and 4% in the placebo group. 

CONCLUSIONS Obeticholic acid administered with ursodiol or as monotherapy for 12 months in patients with primary biliary cholangitis resulted in decreases from baseline in alkaline phosphatase and total bilirubin levels that differed significantly from the changes observed with placebo. There were more serious adverse events with obeticholic acid. 


Funded by Intercept Pharmaceuticals; POISE ClinicalTrials.gov number, NCT01473524; Current Controlled Trials number, ISRCTN89514817.)

Krishan Maggon 's insight:
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis 

Frederik Nevens, M.D., Ph.D., Pietro Andreone, M.D., Giuseppe Mazzella, M.D., Simone I. Strasser, M.B., B.S., M.D., Christopher Bowlus, M.D., Pietro Invernizzi, M.D., Ph.D., Joost P.H. Drenth, M.D., Ph.D., Paul J. Pockros, M.D., Jaroslaw Regula, M.D., Ph.D., Ulrich Beuers, M.D., Michael Trauner, M.D., David E. Jones, M.B., B.Chir., Ph.D., Annarosa Floreani, M.D., Simon Hohenester, M.D., Velimir Luketic, M.D., Mitchell Shiffman, M.D., Karel J. van Erpecum, M.D., Ph.D., Victor Vargas, M.D., Catherine Vincent, M.D., Gideon M. Hirschfield, M.B., B.Chir., Ph.D., Hemant Shah, M.D., M.Sc.C.H., H.P.T.E., Bettina Hansen, Ph.D., Keith D. Lindor, M.D., Hanns-Ulrich Marschall, M.D., Ph.D., Kris V. Kowdley, M.D., Roya Hooshmand-Rad, M.D., Ph.D., Tonya Marmon, Dr.P.H., Shawn Sheeron, B.S.N., M.B.A., Richard Pencek, Ph.D., Leigh MacConell, Ph.D., Mark Pruzanski, M.D., and David Shapiro, M.B., Ch.B., for the POISE Study Group* 

N Engl J Med 2016; 375:631-643August 18, 2016
DOI: 10.1056/NEJMoa1509840
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Hepatitis C Diagnostic Summit | Training Resources | Conferences & Meetings | Resource Center | Division of Viral Hepatitis | CDC

Hepatitis C Diagnostic Summit | Training Resources | Conferences & Meetings | Resource Center | Division of Viral Hepatitis | CDC | Hepatitis C New Drugs Review | Scoop.it
Learn abt #HCV Diagnostic Summit on Sept 8 & 9th. Register today to discuss advances in #hepC lab & diagnostic tech https://t.co/hV49mvIUJO
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation

Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation | Hepatitis C New Drugs Review | Scoop.it
Conclusions Treating PWID with moderate or mild HCV with IFN-free DAAs is cost-effective compared to delay until cirrhosis, except when chronic HCV prevalence and reinfection risk is very high.
Krishan Maggon 's insight:
Journal of Hepatology Volume 65, Issue 1, July 2016, Pages 17–25. doi:10.1016/j.jhep.2016.02.007
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Liver Cancer and Viral Hepatitis | Featured Topics | Division of Viral Hepatitis | CDC

Liver Cancer and Viral Hepatitis | Featured Topics | Division of Viral Hepatitis | CDC | Hepatitis C New Drugs Review | Scoop.it
DYK that together, #hepB & #hepC represent the primary cause of chronic #liver disease & #livercancer? Learn more https://t.co/w5jE3xj8L3
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Detecting hepatic nodules and identifying feeding arteries of hepatocellular carcinoma: efficacy of cone-beam computed tomography in transcatheter arterial chemoembolization

Detecting hepatic nodules and identifying feeding arteries of hepatocellular carcinoma: efficacy of cone-beam computed tomography in transcatheter arterial chemoembolization | Hepatitis C New Drugs Review | Scoop.it
The journal focuses on all topics related to hepatoma.Articles in the following areas are especially welcome: Pathogenesis, clinical examination and diagnosis of hepatoma; Complications of hepatoma, and their preventions and treatments etc.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs

New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs | Hepatitis C New Drugs Review | Scoop.it
Scientists report that a specialized drug screen test using lab-grown human cells has revealed two classes of compounds already in the pharmaceutical
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Eliminating Screening Barriers for HCV

Eliminating Screening Barriers for HCV | Hepatitis C New Drugs Review | Scoop.it
Approximately 3.9 million Americans are chronically infected with the hepatitis C virus (HCV), making it the most common chronic bloodborne infection in the United States, according to the CDC.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Study Looks at Barriers to Hepatitis C Treatment

Study Looks at Barriers to Hepatitis C Treatment | Hepatitis C New Drugs Review | Scoop.it
Beyond high cost, people with hepatitis C face several barriers to treatment, and those arise from various sources.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Overview - Hepatitis C - Mayo Clinic

Overview - Hepatitis C - Mayo Clinic | Hepatitis C New Drugs Review | Scoop.it
Hepatitis C — Comprehensive overview covers symptoms, treatment of infection with the hepatitis C virus.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Effect of coinfection with hepatitis C virus on survival of... : Current Opinion in HIV and AIDS

Effect of coinfection with hepatitis C virus on survival of... : Current Opinion in HIV and AIDS | Hepatitis C New Drugs Review | Scoop.it
Purpose of review: Hepatitis C virus (HCV) coinfection is a common and an important comorbidity in H

Summary: Early cART and wider HCV treatment have the potential to markedly reduce HCV-related mortality and thus increase survival overall for HIV-infected populations. However, HCV treatment will need to be greatly scaled up. Given the complex nature of the populations affected, future studies will need to be carefully designed and controlled to rigorously evaluate the impact of these revolutionary therapies on survival.
Krishan Maggon 's insight:
Current Opinion in HIV & AIDS: September 2016 - Volume 11 - Issue 5 - p 521–526 doi: 10.1097/COH.0000000000000292 SURVIVAL IN THE MODERN ART ERA: Edited by Margaret May and Dominique Costagliola
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Countries With The Highest Incidence Of Liver Cancer In The World

Countries With The Highest Incidence Of Liver Cancer In The World | Hepatitis C New Drugs Review | Scoop.it
Liver cancer is the sixth most common cancer in the world, with Mongolia having the highest incidence rate of this cancer.

WORLD FACTS Countries With The Highest Incidence Of Liver Cancer In The World Liver cancer is the sixth most common cancer in the world, with Mongolia having the highest incidence rate of this cancer. Countries With The Highest Incidence Of Liver Cancer In The World A human liver cross-section, showing multiple tumor deposits. Cancer is currently one of the leading non-communicable diseases around the world. Cancer, if not detected at an early stage will lead to death. Liver cancer is widespread around the world. However, countries with the highest incidences of this type of cancer include; 

 Mongolia Mongolia leads the world with the highest incidences of liver cancer, six times the global average with an age-standardized rate of 78.1 per 100,000. Alcohol dependency among the Mongolians is the major contributing factor to liver cancer in the country. An adult in the country drinks an average of 3 liters of both locally processed and imported pure spirit every day. Liver cancer remains the leading cause of death across gender though men are at a higher risk. 52% of the males and 47% of the female are likely to die from liver cancer in the country. Moreover, 3 in every ten deaths are liver cancer related. The situation is made worse by the fact that the health officials in the country and Asia do not give attention to liver cancer. The country channels most of its health resources to fighting HIV. 

Lao PDR Liver cancer is becoming a health concern in Lao PDR. The country has the highest leading cause of liver cancer in the South East Asia. Liver cancer in Lao PDR is mainly caused by the alcohol consumption, in particular among the adult population. The country has no official registry for liver cancer deaths but it is estimated than one in every ten deaths is liver cancer related. The country has no capacity to treat cancer thus most of the patients are referred to countries like India for specialized treatment. According to World Cancer Research Fund, cases of liver cancer are standardized at 52.6 per 100000 people. 

The Gambia Liver cancer is the most common cancer in Gambia with a standardized age of 25.8 per 100000 people. The cause of this type of cancer is mainly by hepatitis B virus infection. HBV is endemic in the country with 15% to 20% of the population being carriers of the virus. The geographical location of Gambia influences the infection of the liver causing HBV and HCV. Another cause of the widespread liver cancer is the consumption of the dietary aflatoxin. In Gambia, the male-to-female ratio of the liver affected patients stands at 4:1. What Are The Options For Treatment? Highest incidences of liver cancer are reported in Africa and Asia with Latin America recording the lowest incidences. Other countries with the highest prevalence of liver cancer include Egypt, Vietnam, Korean Republic, Thailand, China, Cambodia, and Guinea.The treatment for liver cancer especially at early stages is surgery (partial hepatectomy) other options include radiofrequency ablation, alcohol (ethanol) injection or chemoembolization. At advanced stages of hepatocellular cancer (HCC), a biological therapy known as Sorafenib is an option. 

Countries With The Highest Incidence Of Liver Cancer In The World Rank Country Age-Standardised Rate per 100,000 (World) 1 Mongolia 78.1 2 Lao PDR 52.6 3 The Gambia 25.8 4 Egypt 25.6 5 Viet Nam 24.6 6 Korea, Republic of 22.8 7 Thailand 22.3 8 China 22.3 9 Cambodia 22.0 10 Guinea 19.5
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

MemPro™ Virus-like Particles (VLPs) - Creative Biostructure

MemPro™ Virus-like Particles (VLPs) - Creative Biostructure | Hepatitis C New Drugs Review | Scoop.it
Creative Biostructure can use MemPro™ Virus-like Particles to isolate membrane proteins efficiently.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Hepatitis Education Canada | Programme canadien d’éducation sur l’hépatite

Hepatitis Education Canada | Programme canadien d’éducation sur l’hépatite | Hepatitis C New Drugs Review | Scoop.it
Stigma & Discrimination People living with hepatitis C (HCV) frequently report experiences of stigma in health care settings. Stigma increases the burden of the disease as it can lead to a lack of testing, treatment and primary care.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Liver immunology: How to reconcile tolerance with autoimmunity. - PubMed - NCBI

Liver immunology: How to reconcile tolerance with autoimmunity. - PubMed - NCBI | Hepatitis C New Drugs Review | Scoop.it
Clin Res Hepatol Gastroenterol. 2016 Aug 12. pii: S2210-7401(16)30095-X. doi: 10.1016/j.clinre.2016.06.003. [Epub ahead of print] REVIEW

Summary There are several examples of liver tolerance: the relative ease by which liver allografts are accepted and the exploitation of the hepatic microenvironment by the malarial parasite and hepatotrophic viruses are notable examples. The vasculature of the liver supports a unique population of antigen presenting cells specialised to maintain immunological tolerance despite continuous exposure to gut-derived antigens. Liver sinusoidal endothelial cells and Kupffer cells appear to be key to the maintenance of immune tolerance, by promoting T cell anergy or deletion and the generation of regulatory cell subsets. Despite this, there are three liver diseases with likely autoimmune involvement: primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis. How can we reconcile this with the inherent tolerogenicity of the liver? Genetic studies have uncovered several associations with genes involved in the activation of the innate and adaptive immune systems. There is also evidence pointing to pathogenic and xenobiotic triggers of autoimmune liver disease. Coupled to this, impaired immunoregulatory mechanisms potentially play a permissive role, allowing the autoimmune response to proceed.
Krishan Maggon 's insight:
Clinics and Research in Hepatology and Gastroenterology Available online 12 August 2016 
 In Press, Corrected Proof — Note to users
Charlotte R. Grant1, Rodrigo Liberal

doi:10.1016/j.clinre.2016.06.003
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Comprehensive New Database an “Efficient and Helpful Tool” for Accessing HCV Research

Comprehensive New Database an “Efficient and Helpful Tool” for Accessing HCV Research | Hepatitis C New Drugs Review | Scoop.it
“Each entry contains contextual information pertaining to the entry such as the HCV genotypic background and links to the original publication,” say the authors.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

First NGS full genome characterization of a hepatitis C virus genotype 7 divergent subtype. - PubMed - NCBI

First NGS full genome characterization of a hepatitis C virus genotype 7 divergent subtype. - PubMed - NCBI | Hepatitis C New Drugs Review | Scoop.it
Clin Microbiol Infect. 2016 Aug 8. pii: S1198-743X(16)30289-0. doi: 10.1016/j.cmi.2016.07.032. [Epub ahead of print]

Abstract 

OBJECTIVES: We report the near full length genome sequence, of an hepatitis C virus isolate from a man originating from Democratic Republic of Congo, whose genotype could not be determined by the routinely used sequence technique. 
METHODS: The near-complete genome sequence of this variant BAK1 was obtained by the association of two next generation sequencing technologies. 
RESULTS: Evolutionary analysis indicates that this isolate BAK1 could be the first reported strain belonging to a new HCV-7b subtype. This new subtype has been incorrectly identified as genotype 2 by Versant HCV Genotype 2.0 assay (LiPA). 
CONCLUSION: The requirement of three independent isolates has been filled and a new subtype can be assigned. More examples of HCV-7 are required to better understand its origin, its pathogenicity and its relationship with genotype 2.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Hepatitis B Developers Try To Repeat Gilead's Hep C Trick

Hepatitis B Developers Try To Repeat Gilead's Hep C Trick | Hepatitis C New Drugs Review | Scoop.it
When Roche (OTCQX:RHHBY) pulled out of an alliance with Inovio (NASDAQ:INO) two weeks ago to develop a hepatitis B treatment, it might have seemed like the Swis
more...
No comment yet.